首页>
外国专利>
APPLICATION OF THE COMBINATION OF TERIFLUNOMIDE AND INTERFERON BETA FOR THE TREATMENT OF MULTIPLE SCLEROSIS
APPLICATION OF THE COMBINATION OF TERIFLUNOMIDE AND INTERFERON BETA FOR THE TREATMENT OF MULTIPLE SCLEROSIS
展开▼
机译:特氟苯胺和干扰素β联合治疗多发性硬化症的应用
展开▼
页面导航
摘要
著录项
相似文献
摘要
1. A method of treating a relapsing-remitting form of multiple sclerosis in a patient in need thereof, comprising administering to the patient approximately 7 mg or approximately 14 mg of teriflunomide and a pharmaceutically effective amount of interferon beta-1a or -1b.2. The method of claim 1, comprising administering to the patient approximately 7 mg or approximately 14 mg of teriflunomide once a day and a stable dose of interferon beta-1a or -1b. 3. An effective clinical trial method for treating a relapsing-remitting form of multiple sclerosis in a patient in need thereof, comprising administering to the patient approximately 7 mg or approximately 14 mg of teriflunomide once a day and a stable dose of interferon beta-1a or -1b.4. A method for reducing the number of T1-Gd foci in a patient suffering from a relapsing-remitting form of multiple sclerosis, comprising administering to the patient about 7 mg or about 14 mg of teriflunomide and a pharmaceutically effective amount of interferon beta-1a or -1b.5. The method according to claim 4, comprising administering to the patient approximately 7 mg or approximately 14 mg of teriflunomide once a day and a stable dose of interferon beta-1a or -1b. An effective, clinically proven method for reducing the number of T1-Gd foci in a patient suffering from a relapsing-remitting form of multiple sclerosis, comprising administering to the patient approximately 7 mg or approximately 14 mg of teriflunomide once a day and a stable dose of interferon beta-1a or -1b. 7. A method for reducing the number of T1-Gd foci in a patient suffering from a relapsing-remitting form of multiple sclerosis, comprising administering to the patient approximately
展开▼